ABCL Earnings Date: Nov 9, 2026 (Estimated) — AbCellera Biologics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ABCL's next earnings date?
AbCellera Biologics Inc. (ABCL) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.18 on revenue of $6.2M.
How did ABCL do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), AbCellera Biologics Inc. posted EPS of -$0.18 versus the -$0.16 estimate, a miss of 5.9%. Revenue was $4.0M against a $7.8M estimate. The stock's 1-day post-earnings move was +10.3%.
How much does ABCL stock move after earnings?
ABCL beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About AbCellera Biologics Inc.
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -0.16 | -0.18 | -5.88% | $4.0M | ❌ Miss | +10.30% | +74.92% | +95.44% |
| 2026-05-11 | Q1 2026 | -0.20 | -0.14 | +30.00% | $8.3M | ✅ Beat | -5.71% | -20.76% | -3.05% |
| 2026-02-24 | Q4 2025 | -0.18 | -0.03 | +83.33% | $44.9M | ✅ Beat | -0.93% | +15.22% | +5.28% |
| 2025-11-06 | Q3 2025 | -0.17 | -0.19 | -11.76% | $9.0M | ❌ Miss | -13.69% | -20.09% | -20.75% |
| 2025-08-07 | Q2 2025 | -0.17 | -0.12 | +29.41% | $17.1M | ✅ Beat | +0.24% | +6.13% | -1.65% |
| 2025-02-27 | Q4 2024 | -0.15 | -0.12 | +20.00% | $5.1M | ✅ Beat | -11.47% | -18.49% | -20.89% |
| 2024-11-04 | Q3 2024 | -0.15 | -0.17 | -13.33% | $6.5M | ❌ Miss | -5.88% | +9.00% | +0.35% |
| 2024-08-06 | Q2 2024 | -0.14 | -0.13 | +7.14% | $7.3M | ✅ Beat | -7.72% | -6.32% | -14.74% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $4.0M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Research Fees | 96.3% | $3.9M | -41.2% | $10.2M | $4.1M | $6.6M | $8.8M |
| Licensing and Royalty Revenue | 3.7% | $149K | — | — | — | — | — |
By region
FY2025 · $75.1M total · annual
| Segment | Share | Revenue | YoY | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| CANADA | 85.2% | $64.0M | +144.3% | $484.2M | $36.0M | $26.2M | $64.0M |
| UNITED STATES | 14.8% | $11.1M | +311.1% | $1.2M | $2.0M | $2.7M | $11.1M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.